Jefferies Financial Group posted a marked improvement in profitability for the second quarter, reporting that profit attributable to common shareholders climbed to $226.2 million, or $1.02 per share, for the three months ended May 31. That compares with $88 million, or $0.40 per share, in the same period a year earlier.
The investment bank said the rise in earnings was underpinned by higher fees from advisory engagements and a robust new-issue market. Advisory revenue jumped 47% year-over-year to a record $674.1 million for the quarter, while overall investment banking net revenues increased 57.5% to a record $1.21 billion.
Management framed the quarter as evidence of progress in expanding its corporate M&A capabilities while continuing to concentrate on sponsor-led activity. In a statement, Jefferies CEO Richard Handler and President Brian Friedman said the bank remains encouraged about the second half of 2026 based on a healthy backlog and recent new business bookings.
Several large transactions drove advisory revenue during the quarter. Jefferies advised Sun Pharmaceutical of India on its $11.75 billion acquisition of U.S. drugmaker Organon. The firm also worked on Kelonia Therapeutics’ sale to Eli Lilly of the U.S., a deal valued at up to $7 billion.
Equity capital markets activity contributed materially to the quarter’s strength. Equity underwriting revenue more than tripled to $370.7 million as new issuance remained resilient and private equity sponsors monetized holdings through secondary offerings. Jefferies acted as joint global coordinator on a $6.3 billion share sale in Swiss skincare company Galderma by a group of shareholders in March, which the firm characterized as the largest sponsor-backed block trade ever. The bank was also a bookrunner on major U.S. initial public offerings during the period, including nuclear reactor developer X-Energy and aerospace parts maker Arxis.
Trading activity added to the company’s momentum, as persistent market volatility prompted investors to reshuffle portfolios and hedge risks. Jefferies’ capital markets business, which includes its trading desks, generated $799.3 million in revenue for the quarter, a 13.5% year-over-year increase. Equities trading led the performance, rising 14% to a record $600.8 million, while fixed income revenue increased 12%.
The quarterly results offer an early glimpse into broader investment banking trends on Wall Street ahead of full reporting from larger U.S. banks. Jefferies noted that global mergers and acquisitions activity has topped $2.8 trillion this year, with technology, healthcare and utility and energy sectors most prominent in driving deal volumes.
At the same time, the firm acknowledged a recent period of increased scrutiny tied to prior exposures. Jefferies has been working to move beyond difficulties that followed its links to the collapses of British lender Market Financial Solutions and U.S. auto-parts supplier First Brands, events that prompted questions about the firm’s lending standards.
The stock has strengthened in recent months as investor attention shifted toward the momentum in Jefferies’ capital markets businesses and the pickup in deal activity.
This quarter’s numbers underline the role of advisory and equity underwriting fees in supporting profitability for a boutique investment bank positioned to capture sponsor-led transactions and sizeable equity blocks. Management’s outlook hinges on sustaining the current backlog and converting new business bookings into completed mandates.